INBS
INTELLIGENT BIO SOLUTIONS INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.53
+2.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.49
From 52W high−91.46%
Volume13673.00
Market cap$5.07M
P/E (TTM)—
P/S (TTM)1.2x
Div yield—
Key dataOct 19, 2026
Open
$1.49
From 52W high
−91.46%
Volume
13673.00
Market cap
$5.07M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
30.7
MomentumView details →
1D Return
+2.00%
YTD Return
−84.37%
SummaryUpdated Jun 1, 2026
Intelligent Bio Solutions Inc. (NASDAQ:INBS) is a life sciences company founded in 2016 and headquartered in New York, New York. Originally incorporated as GBS Inc., the company changed its name to Intelligent Bio Solutions Inc. in October 2022. The company went public in December 2020 and operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. INBS focuses on developing non-invasive, real-time monitoring and diagnostic tests that can be used by patients and their primary healthcare practitioners, representing a shift away from traditional invasive blood-based testing methods.
Similar companies
Latest newsMore news →
Intelligent Bio Solutions Inc. signed a securities purchase agreement on August 31, 2026, to sell 2,036,659 shares of common stock (or pre-funded warrants) with accompanying Series N-1 and N-2 warrants at a combined price of $2.455 per share, raising gross proceeds of approximately $5.0 million in a private placement to a single institutional investor.47d agoIntelligent Bio Solutions reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by reader installed base and high-margin cartridge growth.61d agoIntelligent Bio Solutions Inc. announced a significant regulatory milestone for its rapid testing unit, causing its shares to surge on Monday.63d ago